Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Dana-Farber Cancer Institute, Boston, MA, USA. ssaboo@partners.org
Sachin S
SS
Saboo
Fiona
F
Fennessy
Lina
L
Benajiba
Jacob
J
Laubach
Kenneth C
KC
Anderson
Paul G
PG
Richardson
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D064847:Multimodal Imaging; D009101:Multiple Myeloma / Q000188:drug therapy*; D049268:Positron-Emission Tomography; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D000077269:Lenalidomide